Indeed, overexpression of PD-L1 is positively correlated with tumor immunotherapies [29], but controversial is how PD-L1, which is already abundantly expressed in tumors, continues to express and increase anti-PD-1 immunotherapy. The gene discussed is PDCD1; the disease is neoplasm.